Excelsior Medical Co., Ltd. (4104.TW)
TWD 86.1
(-0.35%)
TWD 86.1
(-0.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 702.88 Million TWD | -19.2% |
| 2022 | 869.85 Million TWD | 13.08% |
| 2021 | 769.23 Million TWD | -8.76% |
| 2020 | 843.06 Million TWD | 8.82% |
| 2019 | 774.71 Million TWD | 72.06% |
| 2018 | 450.24 Million TWD | -0.51% |
| 2017 | 452.56 Million TWD | 19.25% |
| 2016 | 379.49 Million TWD | 9.0% |
| 2015 | 348.17 Million TWD | 1.36% |
| 2014 | 343.49 Million TWD | 11.29% |
| 2013 | 308.65 Million TWD | -20.1% |
| 2012 | 386.32 Million TWD | -21.38% |
| 2011 | 491.36 Million TWD | 3.44% |
| 2010 | 475 Million TWD | 39.06% |
| 2009 | 341.57 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 173.49 Million TWD | 4.82% |
| 2024 Q1 | 165.51 Million TWD | -14.88% |
| 2023 Q4 | 194.45 Million TWD | -25.64% |
| 2023 Q2 | 260.52 Million TWD | -6.38% |
| 2023 Q3 | 261.5 Million TWD | 0.38% |
| 2023 FY | 702.88 Million TWD | -19.2% |
| 2023 Q1 | 278.28 Million TWD | 34.06% |
| 2022 Q2 | 197.49 Million TWD | -7.27% |
| 2022 Q3 | 251.8 Million TWD | 27.5% |
| 2022 Q4 | 207.58 Million TWD | -17.56% |
| 2022 FY | 869.85 Million TWD | 13.08% |
| 2022 Q1 | 212.98 Million TWD | -4.23% |
| 2021 FY | 769.23 Million TWD | -8.76% |
| 2021 Q3 | 138.31 Million TWD | -7.17% |
| 2021 Q4 | 222.37 Million TWD | 60.78% |
| 2021 Q1 | 158.6 Million TWD | 12.44% |
| 2021 Q2 | 148.99 Million TWD | -6.06% |
| 2020 Q2 | 128.25 Million TWD | -22.06% |
| 2020 Q1 | 164.56 Million TWD | 56.04% |
| 2020 Q3 | 98.1 Million TWD | -23.51% |
| 2020 Q4 | 141.05 Million TWD | 43.78% |
| 2020 FY | 843.06 Million TWD | 8.82% |
| 2019 Q2 | 126.19 Million TWD | -4.64% |
| 2019 Q4 | 105.46 Million TWD | 1.29% |
| 2019 FY | 774.71 Million TWD | 72.06% |
| 2019 Q1 | 132.32 Million TWD | 20.12% |
| 2019 Q3 | 104.11 Million TWD | -17.49% |
| 2018 Q4 | 110.16 Million TWD | 5.22% |
| 2018 FY | 450.24 Million TWD | -0.51% |
| 2018 Q3 | 104.69 Million TWD | 0.93% |
| 2018 Q2 | 103.73 Million TWD | -21.21% |
| 2018 Q1 | 131.65 Million TWD | 54.42% |
| 2017 Q3 | 104.85 Million TWD | -4.91% |
| 2017 Q1 | 152.19 Million TWD | 68.2% |
| 2017 Q2 | 110.26 Million TWD | -27.55% |
| 2017 FY | 452.56 Million TWD | 19.25% |
| 2017 Q4 | 85.25 Million TWD | -18.69% |
| 2016 Q1 | 95.32 Million TWD | -12.07% |
| 2016 Q2 | 95.15 Million TWD | -0.18% |
| 2016 Q3 | 98.53 Million TWD | 3.55% |
| 2016 Q4 | 90.48 Million TWD | -8.17% |
| 2016 FY | 379.49 Million TWD | 9.0% |
| 2015 Q2 | 107.51 Million TWD | 76.54% |
| 2015 Q1 | 60.9 Million TWD | -18.24% |
| 2015 FY | 348.17 Million TWD | 1.36% |
| 2015 Q3 | 71.34 Million TWD | -33.64% |
| 2015 Q4 | 108.41 Million TWD | 51.96% |
| 2014 Q4 | 74.49 Million TWD | -9.47% |
| 2014 Q3 | 82.28 Million TWD | -26.64% |
| 2014 Q1 | 74.56 Million TWD | -30.84% |
| 2014 FY | 343.49 Million TWD | 11.29% |
| 2014 Q2 | 112.16 Million TWD | 50.43% |
| 2013 Q3 | 73.48 Million TWD | 34.59% |
| 2013 Q1 | 72.75 Million TWD | 25.86% |
| 2013 FY | 308.65 Million TWD | -20.1% |
| 2013 Q4 | 107.81 Million TWD | 46.72% |
| 2013 Q2 | 54.59 Million TWD | -24.95% |
| 2012 Q4 | 57.8 Million TWD | -31.06% |
| 2012 Q3 | 83.84 Million TWD | -27.71% |
| 2012 Q2 | 115.98 Million TWD | -8.22% |
| 2012 FY | 386.32 Million TWD | -21.38% |
| 2012 Q1 | 126.37 Million TWD | 25.1% |
| 2011 Q2 | 115.53 Million TWD | -20.28% |
| 2011 Q1 | 144.93 Million TWD | 62.79% |
| 2011 FY | 491.36 Million TWD | 3.44% |
| 2011 Q4 | 101.01 Million TWD | -22.22% |
| 2011 Q3 | 129.87 Million TWD | 12.41% |
| 2010 Q3 | 133.7 Million TWD | 7.69% |
| 2010 FY | 475 Million TWD | 39.06% |
| 2010 Q4 | 89.03 Million TWD | -33.41% |
| 2010 Q1 | 128.09 Million TWD | 0.0% |
| 2010 Q2 | 124.16 Million TWD | -3.07% |
| 2009 FY | 341.57 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Apex Medical Corp. | 194.21 Million TWD | -261.901% |
| OK Biotech Co., Ltd. | -12.06 Million TWD | 5927.226% |
| Applied BioCode Corporation | -186.7 Million TWD | 476.472% |